New Hope for Migraine Sufferers: Optinose Nasal Delivery of Sumatriptan Proves as Effective as Invasive Subcutantaneous InjectionWASHINGTON--(BUSINESS WIRE)--Apr 17, 2008 - At the American Academy of Neurology Annual Meeting, Optinose, the Norwegian drug delivery specialists, today presented Phase I data that could lead to faster, effective and less invasive relief for migraine sufferers. The recently completed trial first demonstrated that Sumatriptan powder delivered intranasally using OptiNose's 2nd generation device has a rapid onset of action and is as effective as subcutaneously administered Sumatriptan in preventing GTN Challenge Induced EEG changes in migraine sufferers.
Optinose CEO Helena Djupesland commented: "There has been great interest in nasal delivery of migraine medications as a way of accelerating onset of action. However progress has been held back by inadequate and variable clinical efficacy, together with side effects such as a bitter aftertaste. The breath-actuated OptiNose device represents a major advance by delivering the drug dose primarily to the highly vascularized mucosa beyond the nasal valve and accelerating onset of action. In our trial, pharmacokinetics data showed that Sumatriptan powder at doses of 10 mg or 20 mg delivered intranasally by the OptiNose device was rapidly absorbed with a median tmax of 20 min, which is 70 minutes earlier than the marketed sumatriptan nasal spray. There were no reports of bad aftertaste. Regarding efficiacy, the trial showed that the mean qEEG changes for Optinose Intrasanal Sumatriptan powder are similar to SC. We now look forward to presenting further Phase II data later in 2008."
Posted: April 2008